Author

SR Olsen

Observed name: S. Olsen

Institutions: University of Modena and Reggio Emilia, Mayo Clinic, Genentech, Mayo Clinic in Florida

Observed institutions: University of Modena and Reggio Emilia, Mayo Clinic, Genentech, Mayo Clinic in Florida

OpenAlex ID: A5082453636

Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial.

2009 · A. Di Leo, P. Francis, et al. · Cancer Research · 6

P1-12-13: Comparative Pharmacokinetics (PK) of Trastuzumab Emtansine (T-DM1) in Patients Who Have or Who Have Not Received Prior Treatment for Human Epidermal Growth Factor 2 (HER2)-Positive Metastatic Breast Cancer (MBC).

2011 · B Wang, P Conte, et al. · Cancer Research · 1

Works count: 2

Citation count: 7

H-index: 1

I10-index: